Wedbush Reiterates Outperform on ORIC Pharmaceuticals, Maintains $14 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten has reiterated his 'Outperform' rating on ORIC Pharmaceuticals (NASDAQ:ORIC), maintaining a price target of $14.
October 23, 2023 | 1:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst has reiterated an 'Outperform' rating on ORIC Pharmaceuticals, with a maintained price target of $14.
The reiteration of the 'Outperform' rating by Wedbush analyst David Nierengarten indicates a positive outlook for ORIC Pharmaceuticals. The maintained price target of $14 also suggests that the analyst believes the stock is undervalued at current levels. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100